This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
13 September 2016
In the version of this article initially published, on page 676, the top of column 3, the article states that Wave Life Sciences hopes to file its first two IND filings this year; it should have said that the application in Huntington's will be filed this year and the one for DMD in 2017. The error has been corrected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. Duchenne muscular dystrophy drugs at the crossroads, as newer agents advance. Nat Biotechnol 34, 675–676 (2016). https://doi.org/10.1038/nbt0716-675
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0716-675
This article is cited by
-
Fresh from the biotech pipeline—2016
Nature Biotechnology (2017)
-
Drugmakers accused of exploiting orphan drug incentives, fueling price problem
Nature Biotechnology (2017)